Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Developmental Dynamics : an Official Publication of the American Association of Anatomists|September 8, 2007
Neural MMP-28 expression precedes myelination during development and peripheral nerve repairSean R Werner, Anthony L Mescher, Anton W Neff, et al.
Kidney International Reports|February 24, 2026
Dulaglutide Effect on Proteins Associated With CKD ProgressionBrandon E McFarlin, Sok Cin Tye, Eiichiro Satake, et al.
Cardiovascular Diabetology|March 29, 2023
Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort studyMichael Kammer, Andreas Heinzel, Karin Hu, et al.
Diabetes, Obesity & Metabolism|August 14, 2025
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetesJulio Rosenstock, Deborah A Robins, Kevin L Duffin, et al.
Diabetes, Obesity & Metabolism|January 19, 2021
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetesJonathan M Wilson, Amir Nikooienejad, Deborah A Robins, et al.
The Lancet. Diabetes & Endocrinology|September 24, 2022
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trialHiddo J L Heerspink, Naveed Sattar, Imre Pavo, et al.
The Journal of Clinical Endocrinology and Metabolism|October 5, 2021
Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 DiabetesValentina Pirro, Kenneth D Roth, Yanzhu Lin, et al.
Diabetes Care|April 16, 2020
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 DiabetesMark L Hartman, Arun J Sanyal, Rohit Loomba, et al.
Diabetes, Obesity & Metabolism|September 20, 2021
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysisJonathan M Wilson, Yanzhu Lin, M Jane Luo, et al.
The Journal of Clinical Endocrinology and Metabolism|May 14, 2026
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 DiabetesMackenzie J Pearson, Jill A Willency, Yanzhu Lin, et al.
Pageof 5